Fiberside Chat (3-GIS): Automation is not autonomous. Why people are needed in data migration.

Stephen Hudak, senior GIS consultant for SSP Innovations in Centennial, CO. Hudak, has spent nearly a decade working in the field of GIS. While contributing to various positions, he has dedicated his time to working on enterprise software implementations and fiber optic data management systems. Joined with Hudak is Kevin Harrelson. Harrelson is the Production Manager of the Data Team for 3-GIS in Decatur, AL. Having worked in GIS for twenty-five years, his tenure with 3-GIS data migration spans nearly a decade.

Many companies struggle to keep up with the latest technology. Hudak and Harrelson agree that customers want fast and clear communication to see if their designs are working and accessible. GIS permits fast data automation for migration. Although manual methods seem like the quick and effective route, they produce significant risks to something going wrong and problem-solving. In the long run, automation saves time and money due to its ability with data migration “set and forget it” said Hudak.

Human in the Loop machine learning strategies keep humans active in building quality automation models by creating feedback touchpoints. Machine learning has allowed automation to take steps forward in efficiency compared to solely relying on a human.

Combining machine learning and human decisions can produce an ongoing evolution by integrating systems. Set up a system with a purpose and a plan. Depending on the problem, it comes down to a sliding scale between the human and machine work ratio. “The last thing you want to do is attempt to solve a problem, but you solve it in a way that creates more work than it’s worth,” said Harrelson. Human engagement allows for a comprehensive cost-benefit analysis within the data migration process. Machine learning is ultimately not an all-or-nothing game.

CONTACT:  

Kevin Harrelson, Production Manager at 3-GIS, kharrelson@3-gis.com  

Stephen Hudak, Senior GIS consultant at SSP Innovations, stephen.hudak@sspinnovations.com 

Visit 3-gis.com to see previous episodes, videos, articles, and other resources   

Subscribe to the podcast on Apple Podcasts and Spotify

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More